传闻BMS剥离中国核心业务，高瓴资本接盘！

市场资讯2025-09-12

（来源：药研网）今日，业内流传的一则消息显示，百时美施贵宝（BMS）中国业务或迎来重大调整。根据网传邮件内容，BMS已签署协议，将其在中美上海施贵宝制药有限公司（SASS）所持有的60%股权，以及数款仅在中国大陆市场制造和销售的关联产品——包括Baraclude（博路定）、Bufferin（百服宁）、Theragran（施尔康）、Monopril和Velosef——出售给Hillhouse投资集团...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2566979823?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-12 19:34","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2566979823","market":"fut","top_or_hot":-1,"title":"传闻BMS剥离中国核心业务，高瓴资本接盘！","media":"市场资讯","content":"<div>\n<p>（来源：药研网）今日，业内流传的一则消息显示，百时美施贵宝（BMS）中国业务或迎来重大调整。根据网传邮件内容，BMS已签署协议，将其在中美上海施贵宝制药有限公司（SASS）所持有的60%股权，以及数款仅在中国大陆市场制造和销售的关联产品——包括Baraclude（博路定）、Bufferin（百服宁）、Theragran（施尔康）、Monopril和Velosef——出售给Hillhouse投资集团...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2025-09-12/doc-infqfwzh9272528.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>传闻BMS剥离中国核心业务，高瓴资本接盘！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n传闻BMS剥离中国核心业务，高瓴资本接盘！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-12 19:34 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/roll/2025-09-12/doc-infqfwzh9272528.shtml><strong>市场资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>（来源：药研网）今日，业内流传的一则消息显示，百时美施贵宝（BMS）中国业务或迎来重大调整。根据网传邮件内容，BMS已签署协议，将其在中美上海施贵宝制药有限公司（SASS）所持有的60%股权，以及数款仅在中国大陆市场制造和销售的关联产品——包括Baraclude（博路定）、Bufferin（百服宁）、Theragran（施尔康）、Monopril和Velosef——出售给Hillhouse投资集团...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2025-09-12/doc-infqfwzh9272528.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0417516738.SGD","symbol_name":"Allianz Hong Kong Equity AT Acc SGD","start_time":0,"source_url":"https://finance.sina.com.cn/roll/2025-09-12/doc-infqfwzh9272528.shtml","article_id":"2566979823","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566979823","pubTimestamp":1757676840,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"今日，业内流传的一则消息显示，百时美施贵宝中国业务或迎来重大调整。BMS在邮件中表示，“此次资产剥离计划反映了公司不断演进的网络战略”，并指出此举有助于BMS将内部资源集中于最具增长潜力的核心领域，同时借助具备本地化制造与市场经验的外部合作伙伴，进一步优化业务布局。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"89618":"京东集团-SWR","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0499858602.USD":"NINETY ONE GSF ASIA PACIFIC EQUITY OPPORTUNITIES \"A\" (USD) ACC","LU0164880469.USD":"HSBC GIF HONG KONG EQUITY \"AC\" ACC","LU0293314216.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"A\" (USD) ACC","IE00B29SXG58.USD":"FSSA CHINA FOCUS \"I\" (USD) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU0370786039.SGD":"Fidelity Greater China A-SGD","SG9999002828.SGD":"Eastspring Investments Unit Trusts - Dragon Peacock A SGD","LU0588545730.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"ADM\" (USD) INC","LU1770036033.HKD":"NINETY ONE GSF ASIAN EQUITY \"A\" (HKD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU1282651048.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AMG\" (USD) INC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0594300419.USD":"富达中国消费基金A","LU1044876610.USD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"ZU\" (USD) ACC","LU0543330483.HKD":"TEMPLETON ASIAN GROWTH \"A\" (HKD) ACC","LU0348805143.USD":"ALLIANZ ENHANCED ALL CHINA EQUITY \"A\" (USD) INC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU1366334578.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"A\" (USD) INC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1610":"ETF&股票定投概念","LU2257852520.SGD":"JPMorgan Funds - Asia Growth A (acc) SGD","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","BK1615":"港股-互联网","BK1575":"同股不同权","LU0588545490.SGD":"Eastspring Investments - Asian Equity Income AS SGD","LU0320764755.SGD":"FTIF - Templeton Asian Growth A Acc SGD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0488056044.USD":"Allianz Asian Multi Income Plus Cl AM DIS USD","LU0384037296.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AT\" (USD) ACC","LU1282649810.SGD":"Allianz Asian Multi Income Plus Cl AMg DIS H2-SGD","LU0084288322.USD":"Natixis Asia Equity RD USD","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU1720050803.USD":"安联全方位中国股票基金","BMS":"碧美斯","LU1282651121.HKD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AMG\" (HKD) INC","LU1224444064.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AM\" (USDHDG) INC","LU0259732245.USD":"EASTSPRING INVESTMENTS DRAGON PEACOCK A","LU0029875118.USD":"TEMPLETON ASIAN GROWTH \"A\" INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC"},"translate_title":"It is rumored that BMS will divest its core business in China, and Hillhouse Capital will take over!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"89618":0.6,"BMS":1},"content_text":"（来源：药研网）今日，业内流传的一则消息显示，百时美施贵宝（BMS）中国业务或迎来重大调整。根据网传邮件内容，BMS已签署协议，将其在中美上海施贵宝制药有限公司（SASS）所持有的60%股权，以及数款仅在中国大陆市场制造和销售的关联产品——包括Baraclude（博路定）、Bufferin（百服宁）、Theragran（施尔康）、Monopril和Velosef——出售给Hillhouse投资集团（高瓴资本）的关联公司。网传邮件，仅供参考该交易预计将于2026年初完成，目前具体交易金额尚未披露。BMS在邮件中表示，“此次资产剥离计划反映了公司不断演进的网络战略”，并指出此举有助于BMS将内部资源集中于最具增长潜力的核心领域，同时借助具备本地化制造与市场经验的外部合作伙伴，进一步优化业务布局。百时美施贵宝是一家全球领先的生物制药企业，自1982年进入中国市场，与上药集团、国药集团共同投资成立了中美上海施贵宝制药有限公司。该企业坐落于上海市闵行区，是中国改革开放后首家中美合资制药企业，具有标志性意义。收购方高瓴资本为亚洲地区管理规模领先的投资机构，以长期结构性价值投资为理念，擅长通过深度研究捕捉产业变革中的投资机会。其投资布局广泛覆盖一级和二级市场，横跨VC、PE、Buyout等多个阶段，医药健康领域一直是高瓴重点关注的赛道之一。\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566979823","isCrawlerRequest":true}